Although current immunotherapies have shown strong potency for human cancer, the efficacy of PD-L1 or PD-1 blockade in OV has been worse than other tumor types—only 11.5–12.3% ORR in PD-L1-positive OV patients while 5.9% ORR in PD-L1-negative OV patients [24]. The gene discussed is CD274; the disease is neoplasm.